Daniel J. Lippis - 08 May 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 May 2025
Net transactions value
-$9,618
Form type
4
Filing time
09 May 2025, 19:35:19 UTC
Previous filing
05 May 2025
Next filing
12 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lippis Daniel J. CVP, JAPAC ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 09 May 2025 0002004380

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +4,225 +19% $0.000000 26,616 08 May 2025 Direct F1
transaction EW Common Stock Options Exercise $14,941 +330 +1.2% $45.28 26,946 09 May 2025 Direct F2
transaction EW Common Stock Sale $24,560 -330 -1.2% $74.42 26,616 09 May 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +21,500 $0.000000 21,500 08 May 2025 Common Stock 21,500 $74.63 Direct F4
transaction EW Performance Rights Award $0 +4,225 $0.000000 4,225 08 May 2025 Common Stock 4,225 Direct F5
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -330 -100% $0.000000 0 09 May 2025 Common Stock 330 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.
F3 This transaction was executed in multiple trades at prices ranging from $74.135 to $74.735. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4 These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F5 Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.